Resources for Patients and Providers on Adalimumab Biosimilars

EP: 1.The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

EP: 2.An Overview of Adalimumab Biosimilars

EP: 3.The Pharmacological Aspects of Adalimumab Biosimilars

EP: 4.The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases

EP: 5.Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings

EP: 6.The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars

EP: 7.Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

EP: 8.Selecting Between Adalimumab Biosimilars for Your Patients

EP: 9.Switching From Adalimumab to a Biosimilar

EP: 10.Clinical Experience With Initiating Adalimumab Biosimilars

EP: 11.The Role of Health Care Providers on Encouraging Adalimumab Biosimilar Use

EP: 12.Copay Assistance Programs for Adalimumab Biosimilars

EP: 13.Common Questions From Patients About Adalimumab Biosimilars

EP: 14.The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars

Now Viewing

EP: 15.Resources for Patients and Providers on Adalimumab Biosimilars

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The conversation delves into various educational resources utilized both by healthcare providers and patients regarding ddalimumab biosimilars. Providers emphasize the importance of authoritative sources such as the FDA and professional societies like the American College of Rheumatology for accurate information on interchangeability and biosimilars.

While some providers note a lack of comprehensive resources, they highlight the American Academy of Dermatology and New Zealand DermNet as useful references. Patient education materials from organizations like the Crohn's and Colitis Foundation are also recommended.

Providers stress the need for proactive patient engagement and filtering information from reliable sources, discouraging reliance on social media or blogs for medical advice. To ensure patient understanding, nurses play a crucial role in creating educational tools and facilitating communication, including preemptive notifications about changes in medication availability.

Overall, the discussion underscores the importance of ongoing education and communication between healthcare providers and patients to optimize treatment outcomes with Adalimumab biosimilars.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.